Allergy and Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh, Edinburgh, United Kingdom.
Euro Surveill. 2015 Feb 26;20(8):21043. doi: 10.2807/1560-7917.es2015.20.8.21043.
To evaluate seasonal trivalent inactivated influenza vaccine effectiveness (VE) in Scotland, we performed a Scotland-wide linkage of patient-level primary care, hospital and virological swab data from 3,323 swabs (pooling data over nine influenza seasons: 2000/01 to 2008/09). We estimated the VE for reducing realtime RT-PCR-confirmed influenza using a test-negative study design. Vaccination was associated with a 57% (95% confidence interval (CI): 31–73) reduction in the risk of PCR-confirmed influenza. VE was 60% (95% CI:22–79) for patients younger than 65 years and clinically at risk of serious complications from influenza, and 19% (95% CI: −104 to 68) for any individual 65 years and older. Vaccination was associated with substantial, sustained reductions in laboratory-confirmed influenza in the general population and younger patients in clinical at-risk groups.
为了评估苏格兰季节性三价灭活流感疫苗的效果(VE),我们对来自 3323 个拭子的患者水平初级保健、医院和病毒学拭子数据(通过九个流感季节的数据进行汇总:2000/01 至 2008/09)进行了苏格兰范围内的链接。我们使用阴性测试研究设计来估计降低实时 RT-PCR 确诊流感的 VE。接种疫苗可使 PCR 确诊流感的风险降低 57%(95%置信区间(CI):31-73)。对于年龄小于 65 岁且有临床严重流感并发症风险的患者,VE 为 60%(95%CI:22-79),而对于任何 65 岁及以上的个体,VE 为 19%(95%CI:-104-68)。接种疫苗与普通人群和临床高危人群中年龄较小的患者的实验室确诊流感的大量持续减少有关。